MCID: SPR005
MIFTS: 37

Superficial Basal Cell Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Superficial Basal Cell Carcinoma

MalaCards integrated aliases for Superficial Basal Cell Carcinoma:

Name: Superficial Basal Cell Carcinoma 12 14 69
Multifocal Superficial Basal Cell Carcinoma 12 69
Superficial Multicentric Basal-Cell Carcinoma 12
Multicentric Basal Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4300
NCIt 47 C4108
SNOMED-CT 64 61098004
UMLS 69 C0334256

Summaries for Superficial Basal Cell Carcinoma

MalaCards based summary : Superficial Basal Cell Carcinoma, also known as multifocal superficial basal cell carcinoma, is related to basal cell carcinoma and squamous cell carcinoma. An important gene associated with Superficial Basal Cell Carcinoma is TLR7 (Toll Like Receptor 7), and among its related pathways/superpathways are IL-2 Pathway and Toll-Like receptor Signaling Pathways. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin and t cells, and related phenotypes are hematopoietic system and immune system

Related Diseases for Superficial Basal Cell Carcinoma

Diseases related to Superficial Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
id Related Disease Score Top Affiliating Genes
1 basal cell carcinoma 10.8
2 squamous cell carcinoma 10.1
3 keratosis 10.0
4 actinic keratosis 10.0
5 tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria 9.9 TLR7 TLR9
6 melanoma 9.9
7 bowen's disease 9.9
8 congenital symblepharon 9.8 BLK TLR9
9 epidermolytic hyperkeratosis 9.7
10 dermatitis 9.7
11 nodular basal cell carcinoma 9.7
12 psoriasis 9.7
13 heavy chain disease 9.7 PTCH1 TLR9
14 diamond-blackfan anemia 1 9.5 BLK TLR9
15 systemic lupus erythematosus 9.2 BLK TLR7 TLR9
16 carotid artery dissection 9.2 TLR7 TLR8 TLR9
17 sarcomatoid basal cell carcinoma 8.0 BLK PTCH1 TLR7 TLR8 TLR9

Graphical network of the top 20 diseases related to Superficial Basal Cell Carcinoma:



Diseases related to Superficial Basal Cell Carcinoma

Symptoms & Phenotypes for Superficial Basal Cell Carcinoma

MGI Mouse Phenotypes related to Superficial Basal Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.55 BLK PTCH1 TLR7 TLR8 TLR9
2 immune system MP:0005387 9.35 BLK PTCH1 TLR7 TLR8 TLR9
3 renal/urinary system MP:0005367 8.92 PTCH1 TLR7 TLR8 TLR9

Drugs & Therapeutics for Superficial Basal Cell Carcinoma

Drugs for Superficial Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
3 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 1,Phase 2
4 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
6 interferons Phase 4,Phase 3,Phase 2,Phase 1
7 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
8 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
9 Anesthetics Phase 3
10 Tea Nutraceutical Phase 2, Phase 3
11
Epinephrine Approved, Vet_approved 51-43-4 5816
12
Lidocaine Approved, Vet_approved 137-58-6 3676
13 Racepinephrine Approved
14
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
15 Epinephryl borate
16 Immunosuppressive Agents
17 Respiratory System Agents
18 Central Nervous System Depressants
19 Adrenergic Agents
20 Adrenergic Agonists
21 Adrenergic alpha-Agonists
22 Adrenergic beta-Agonists
23 Mydriatics
24 Sodium Channel Blockers
25 Neurotransmitter Agents
26 Anesthetics, Local
27 Diuretics, Potassium Sparing
28 Vasoconstrictor Agents
29 Anti-Arrhythmia Agents
30 Anti-Asthmatic Agents
31 Peripheral Nervous System Agents
32 Autonomic Agents
33 Bronchodilator Agents

Interventional clinical trials:

(show all 39)

id Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
3 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Completed NCT00189306 Phase 3 Imiquimod 5% cream
4 Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
5 A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
6 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
7 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
8 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3 Imiquimod
9 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
10 Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma Recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
11 Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma Completed NCT00604890 Phase 2 API 31510 Topical Cream
12 PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities Completed NCT01325688 Phase 2 PEP005 (ingenol mebutate) Gel, 0.05%
13 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma Completed NCT00108134 Phase 2 PEP005
14 To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC Completed NCT00432185 Phase 2 PEP005
15 Photochemical Tissue Bonding Completed NCT00586040 Phase 2
16 Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment Completed NCT00941811 Phase 2 Imiquimod
17 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002975 Phase 2 aminolevulinic acid
18 Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL Recruiting NCT02367547 Phase 1, Phase 2 Hexylaminolevulinate cream;Aminolevulinic Acid Nano Emulsion;Methylaminolevulinate cream
19 Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes Active, not recruiting NCT01700049 Phase 2 vismodegib (150 mg PO daily)
20 Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma Not yet recruiting NCT03035188 Phase 2 Vismodegib
21 To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) Terminated NCT01033019 Phase 2 LDE225 0.75%;Vehicle
22 Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma Terminated NCT01808950 Phase 1, Phase 2 0.06% Resiquimod Gel - A;0.06% Resiquimod Gel - B;0.06% Resiquimod Gel - C
23 Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer Completed NCT01292668 Phase 1 methyl-5-aminolevulinate hydrochloride cream;photodynamic therapy
24 Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 Completed NCT00865644 Phase 1 Imiquimod 5% Cream
25 Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970 Unknown status NCT00639652
26 Mohs Versus Traditional Surgery - Basal-Cell Carcinomas (BCC) Unknown status NCT00699829
27 In-vivo Optical Coherence Tomography Imaging in Dermatooncology Unknown status NCT01680562
28 Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas Completed NCT02125669
29 Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear Completed NCT00218868
30 New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) Completed NCT01482104 MAL-PDT re-treatment;usual MAL-PDT
31 Clinical Diagnosis of Basal Cell Carcinoma Subtype Completed NCT01370824
32 Debulking Effect of Curretage on Basal Cell Carcinomas - a Histological Assessment. Completed NCT00237107
33 Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery Completed NCT01298167
34 Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial Recruiting NCT03012009 MAL;lidocaine hydrochloride 2% with epinephrine
35 Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser Recruiting NCT02270645
36 Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma Active, not recruiting NCT02825511
37 Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease No longer available NCT00535080 Metvix (methyl aminolevulinate)
38 Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas Suspended NCT00515970
39 Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC Terminated NCT00994240

Search NIH Clinical Center for Superficial Basal Cell Carcinoma

Genetic Tests for Superficial Basal Cell Carcinoma

Anatomical Context for Superficial Basal Cell Carcinoma

MalaCards organs/tissues related to Superficial Basal Cell Carcinoma:

39
Skin, T Cells

Publications for Superficial Basal Cell Carcinoma

Articles related to Superficial Basal Cell Carcinoma:

(show top 50) (show all 131)
id Title Authors Year
1
Superficial basal cell carcinoma: Dermoscopic and histopathological features of multiple small erosions. ( 28677117 )
2017
2
Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. ( 28088999 )
2017
3
Superficial basal cell carcinoma treated with 70% trichloroacetic acid applied topically: a case study. ( 28260938 )
2017
4
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical methylaminolevulinic acid: results of a randomized controlled trial. ( 28886209 )
2017
5
Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma: A Randomized Clinical Trial. ( 28793140 )
2017
6
Ambulatory Photodynamic Therapy for Superficial Basal Cell Carcinoma: An Effective Light Source? ( 28093601 )
2017
7
Photodynamic therapy with epidermal ablation using fractional CO2 laser for treating superficial basal cell carcinoma: A case series. ( 28647617 )
2017
8
Patient preferences for the attributes of a non-invasive treatment for superficial Basal cell carcinoma: a discrete choice experiment. ( 28667739 )
2017
9
Superficial basal cell carcinoma: A comparison of superficial only subtype with superficial combined with other subtypes by age, sex and anatomic site in 3150 cases. ( 28493477 )
2017
10
Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%. ( 27574458 )
2016
11
Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. ( 27359199 )
2016
12
Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015. ( 27904293 )
2016
13
Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma - a prospective, consecutive, cohort study of 168 cases. ( 27146027 )
2016
14
Preoperative prediction of histopathologic outcome in basal cell carcinoma - flat surface and multiple small erosions predict superficial basal cell carcinoma in lighter skin types. ( 26921200 )
2016
15
Three year follow-up results of photodynamic therapy versus imiquimod versus fluorouracil for treatment of superficial basal cell carcinoma: a single blind, non-inferiority, randomized controlled trial. ( 27113429 )
2016
16
The effect of topical diclofenac 3% and calcitriol 3A I1g/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial. ( 27067393 )
2016
17
Superficial Basal Cell Carcinoma on the Face is a Diagnostic Challenge. ( 27057051 )
2016
18
Reflectance confocal microscopy and dermoscopy for in vivo, non-invasive skin imaging of superficial basal cell carcinoma. ( 27123056 )
2016
19
Two-fold illumination in topical 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) for superficial basal cell carcinoma (sBCC): A retrospective case series and cohort study. ( 26774689 )
2016
20
Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis? ( 27256516 )
2016
21
Surgery Versus 5% Imiquimod for NodularA and Superficial Basal Cell Carcinoma: 5-Year Results of the SINSA Randomized Controlled Trial. ( 27932240 )
2016
22
Superficial basal cell carcinoma. ( 27914672 )
2016
23
Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients. ( 25925162 )
2015
24
New I+-papillomavirus 4 isolate in a verruca vulgaris with multicentric superficial basal cell carcinoma. ( 25557421 )
2015
25
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal. ( 25581584 )
2015
26
Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ on the trunk and extremities with ablative fractional laser-assisted delivery of topical fluorouracil. ( 25687314 )
2015
27
The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma: reply from the authors. ( 26154079 )
2015
28
The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma. ( 26146762 )
2015
29
Melanoma in situ or superficial basal cell carcinoma? ( 26158373 )
2015
30
Pulsed dye laser treatment of superficial basal cell carcinoma. ( 25776237 )
2015
31
Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU). ( 25935596 )
2015
32
Treatment of choice in superficial basal cell carcinoma. ( 25776243 )
2015
33
The importance of superficial basal cell carcinoma in a retrospective study of 139 patients who underwent Mohs micrographic surgery in a Brazilian university hospital. ( 26602517 )
2015
34
Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'. ( 25581586 )
2015
35
Subcutaneous Sarcoidal Granuloma Underlying Superficial Basal Cell Carcinoma. ( 26677309 )
2015
36
Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'. ( 25581585 )
2015
37
Biallelic alterations of the large tumor suppressor 1 (LATS1) gene in infiltrative, but not superficial, basal cell carcinomas in a Japanese patient with nevoid basal cell carcinoma syndrome. ( 25119020 )
2014
38
A case of scrotal superficial basal cell carcinoma caused by chronic arsenic exposure. ( 24566581 )
2014
39
Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05% ( 25052730 )
2014
40
Discordant expression of desmoglein 2 and 3 at the mRNA and protein levels in nodular and superficial basal cell carcinoma revealed by immunohistochemistry and fluorescent in situ hybridization. ( 24934917 )
2014
41
Immunocryosurgery for Non-superficial Basal Cell Carcinoma: A Pro-spective, Open-label Phase III Study for Tumours a8oa882 cm in Diameter. ( 23722308 )
2014
42
Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. ( 24749843 )
2014
43
The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial. ( 25040296 )
2014
44
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. ( 24332516 )
2014
45
Photodynamic therapy versus topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a non-inferiority randomised controlled trial. ( 25066012 )
2014
46
Spoke wheel-like structures in superficial basal cell carcinoma: a correlation between dermoscopy, histopathology, and reflective confocal microscopy. ( 24124839 )
2013
47
Applicability of dermoscopy for evaluation of patients' response to non-ablative therapies for the treatment of superficial basal cell carcinoma. ( 24283541 )
2013
48
Dermal changes in superficial basal cell carcinoma, melanoma in situ and actinic keratosis and their implications. ( 24117926 )
2013
49
Combined Carbon Dioxide Laser with Photodynamic Therapy for Nodular and Superficial Basal Cell Carcinoma: Almost Scarless Cure With Minimal Recurrence. ( 23407256 )
2013
50
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. ( 23683751 )
2013

Variations for Superficial Basal Cell Carcinoma

Expression for Superficial Basal Cell Carcinoma

Search GEO for disease gene expression data for Superficial Basal Cell Carcinoma.

Pathways for Superficial Basal Cell Carcinoma

Pathways related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 BLK TLR7 TLR8 TLR9
2
Show member pathways
12.55 TLR7 TLR8 TLR9
3
Show member pathways
12.46 TLR7 TLR8 TLR9
4
Show member pathways
12.2 TLR7 TLR8 TLR9
5
Show member pathways
12.07 BLK TLR7 TLR8 TLR9
6
Show member pathways
11.85 TLR7 TLR8 TLR9
7 11.83 TLR7 TLR8 TLR9
8 11.71 TLR7 TLR8 TLR9
9
Show member pathways
11.64 TLR7 TLR8 TLR9
10
Show member pathways
11.53 TLR7 TLR8 TLR9
11
Show member pathways
11.44 TLR7 TLR8 TLR9
12 11.42 BLK TLR7 TLR8 TLR9
13 11.4 TLR7 TLR9
14 11.06 TLR7 TLR8 TLR9

GO Terms for Superficial Basal Cell Carcinoma

Cellular components related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.5 TLR7 TLR8 TLR9
2 endosome membrane GO:0010008 9.33 TLR7 TLR8 TLR9
3 phagocytic vesicle GO:0045335 9.26 TLR7 TLR9
4 early phagosome GO:0032009 8.96 TLR7 TLR9
5 endolysosome membrane GO:0036020 8.8 TLR7 TLR8 TLR9

Biological processes related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.9 PTCH1 TLR7 TLR8 TLR9
2 immune system process GO:0002376 9.76 TLR7 TLR8 TLR9
3 inflammatory response GO:0006954 9.73 TLR7 TLR8 TLR9
4 innate immune response GO:0045087 9.71 BLK TLR7 TLR8 TLR9
5 cellular response to mechanical stimulus GO:0071260 9.59 TLR7 TLR8
6 positive regulation of inflammatory response GO:0050729 9.58 TLR7 TLR9
7 regulation of protein phosphorylation GO:0001932 9.57 TLR7 TLR8
8 positive regulation of interleukin-6 production GO:0032755 9.55 TLR7 TLR9
9 positive regulation of interleukin-8 production GO:0032757 9.54 TLR7 TLR9
10 toll-like receptor signaling pathway GO:0002224 9.54 TLR7 TLR8 TLR9
11 positive regulation of NF-kappaB import into nucleus GO:0042346 9.52 TLR7 TLR9
12 positive regulation of chemokine production GO:0032722 9.51 TLR7 TLR9
13 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.5 TLR7 TLR8 TLR9
14 microglial cell activation GO:0001774 9.49 TLR7 TLR8
15 I-kappaB phosphorylation GO:0007252 9.48 TLR7 TLR9
16 regulation of cytokine secretion GO:0050707 9.46 TLR8 TLR9
17 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.43 TLR7 TLR8
18 toll-like receptor 9 signaling pathway GO:0034162 9.43 TLR7 TLR8 TLR9
19 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.33 TLR7 TLR8 TLR9
20 positive regulation of interferon-beta biosynthetic process GO:0045359 9.13 TLR7 TLR8 TLR9
21 positive regulation of interferon-alpha biosynthetic process GO:0045356 8.8 TLR7 TLR8 TLR9

Molecular functions related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.26 TLR7 TLR8
2 double-stranded RNA binding GO:0003725 9.16 TLR7 TLR8
3 single-stranded RNA binding GO:0003727 8.96 TLR7 TLR8
4 siRNA binding GO:0035197 8.62 TLR7 TLR9

Sources for Superficial Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....